open/close global search bar

25 April 2012 by Harm Jan Bogaard

Conference talk

HJ Bogaard: The Most Important Target of Therapy in Advanced WHO Category 1 Pulmonary Hypertension is the Right Ventricle

All credit to Dr. HJ Bogaard FPVRI, VU Medisch Centrum, Amsterdam, The Netherlands

A presentation from the 5th Joint SAPH/PVRI Annual Meeting in Istanbul, 24-27th April 2012

 

Additional key-words:  therapy,pro-con,right heart,Sugen Hypoxia

About the author

profile picture of Harm Jan Bogaard

Harm Jan Bogaard

Professor

VU University Medical Center Amsterdam

Netherlands

Related Content

Right ventricular systolic pressure (RVSP) of hypoxic mutant (D849N) mice receiving imatinib. thumbnail image

Atlas image

01 January 2015

{{GlobalController.truncateTitle("Right ventricular systolic pressure (RVSP) of hypoxic mutant (D849N) mice receiving imatinib.", 65)}}
Right ventricular hypertrophy in hypoxic mutant (D849N) mice receiving imatinib thumbnail image

Atlas image

01 January 2015

{{GlobalController.truncateTitle("Right ventricular hypertrophy in hypoxic mutant (D849N) mice receiving imatinib", 65)}}
Muscularization of pulmonary vessels in hypoxic mutant (D849N) mice receiving imatinib thumbnail image

Atlas image

01 January 2015

{{GlobalController.truncateTitle("Muscularization of pulmonary vessels in hypoxic mutant (D849N) mice receiving imatinib", 65)}}
Riociguat and sildenafil attenuate secondary pulmonary hypertension in a model of left heart failure thumbnail image

Abstract

27 January 2014

{{GlobalController.truncateTitle("Riociguat and sildenafil attenuate secondary pulmonary hypertension in a model of left heart failure", 65)}}
Clinical evaluation of the RV-PA interaction using pulmonary vascular impedance and pressure-volume loops thumbnail image

Abstract

27 January 2014

{{GlobalController.truncateTitle("Clinical evaluation of the RV-PA interaction using pulmonary vascular impedance and pressure-volume loops", 65)}}

Add to reading list

Please enter a list name.

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg